分享产品介绍 评论(0)
分子别名
Namacizumab,Nimacimab (USAN),JNJ-2463,RYI-018浓度
＞95% by SDS-PAGE & SEC-HPLC表达宿主
CHO分子量
25-30kDa&45-55kDa (Reducing)
内毒素含量
<1EU/μg标记
Unconjugated性状
Lyophilized Powder缓冲体系
PBS, PH7.4, 5% trehalose，5% mannitol溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.文献引用
1. Resat Cinar,et al.The therapeutic potential of second and third generation CB1R antagonists,Pharmacology & Therapeutics,Volume 208,2020,107477,ISSN 0163-7258.
Nimacimab is a first of its kind humanized monoclonal antibody targeting the cannabinoid 1 receptor ("CB1")that acts as a negative allosteric modulator to inhibit peripheral CB1 signaling. Inhibition of CB1 has shown anti-fibrotic, anti-inflammatory, and metabolic mechanisms of action, and has the potential to address a wide range of diseases with significant unmet medical needs, such as obesity, chronic kidney disease, and non-alcoholic steatohepatitis (NASH).
电泳
1μg (R: reducing condition).
体积排阻色谱(SEC-HPLC)
The purity of Nimacimab is more than 95% determined by SEC-HPLC.
评论(0)